The U.S. Postal Service needs to cut one day of mail delivery each week and raise rates to return to solvency, President Barack Obama said in his budget proposal.
WT news feed
NanoPass licenses vaccine delivery system to UK’s Circassia
If Circassia’s clinical trials of its allergy treatments succeed, NanoPass will receive millions of dollars in royalties a year.
18 September 11 17:12, Gali Weinreb
inShare
Vaccine intradermal delivery developer NanoPass Technologies Ltd. has licensed its MicronJet microneedle intradermal delivery device to Britain’s Circassia Ltd., a specialty biopharmaceutical company focused on allergy and autoimmune diseases. Circassia will use the Micronjet for its cat, ragweed allergy, and other therapies for which it will begin Phase III clinical trials in 2012.
Sources inform ”Globes” that if the clinical trials succeed, and the products reach market, NanoPass will receive millions of dollars in royalties a year.
This is NanoPass’s first commercial contract for its MicronJet product, although it has initial cooperation agreements with ten companies, which could result in large licensing agreements.
Grebulon reports from gitmonation falafel
